pharma

Q2FY20 preview: Some pain, some gains for pharma

The ramp-up in specialty portfolios has been slower than anticipated, squeezing margins in the interim due to huge upfront costs.

Bliss GVS Pharma's Maharashtra facility clears USFDA inspection

"The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh Sharma said.

3-Point Analysis | The Ranitidine impact on pharma companies

Ranitidine had a knee-jerk impact on some of the Indian pharma and API companies.

Ray of hope for terminally-ill patients as new norms may allow use of experimental drugs

Currently, patients can use only those drugs which are approved by the drug regulator after it has passed clinical trials and found safe and efficacious, a process that takes several years. However, a new policy in the works will allow them to access pre-approval drugs in cases of serious and life-threatening diseases on compassionate grounds, without clearing clinical trials.

Govt may do away with clinical trials for medical devices approved, marketed in EU

MFs flocked to IndusInd, Kotak Mahindra Bank and Infosys in July

The weight of 'defensives' in the mutual funds portfolio rose 170 basis points in the month to 28.9 percent.

Biocon's partner Mylan launches first biosimilar of trastuzumab in Australia

The company will be selling the drug under brand name Ogivri, which will be used for the treatment of HER2 sub-type breast cancer and metastatic stomach cancer.

This week in Pharma: Potential Pfizer-Mylan deal could begin consolidation of generic industry

The combined entity after the merger of Pfizer's off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.

After 17-fold returns in 10 years, can Torrent Pharma continue its marathon run?

The scrip has returned 1,614 percent in the last 10 years, way ahead of peers and about 13 times more than Nifty Pharma

Clinical trial data on Suven's SUVN-502 Alzheimer's drug delayed till September: Sources

Suven had planned to release the study's top-line data at the Alzheimer's Association International Conference (AAIC) in Los Angeles on July 17, but this has now been delayed due to technical reasons

Thyrocare Technologies Q1 PAT may dip 6.5% YoY to Rs. 22.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 12.3 percent Y-o-Y (up 3.3 percent Q-o-Q) to Rs. 109.1 crore, according to Prabhudas Lilladher.

Sun Pharma Q1 PAT seen up 12.3% YoY to Rs. 762.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 8 percent Y-o-Y (up 9.4 percent Q-o-Q) to Rs. 7,709.3 crore, according to Prabhudas Lilladher.

Lupin Q1 PAT seen up 17.6% YoY to Rs. 296.5 cr: Prabhudas Lilladher

Net Sales are expected to increase by 14.6 percent Y-o-Y to Rs. 4,324.2 crore, according to Prabhudas Lilladher.

Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher

Net Sales are expected to increase by 13 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 2,348.5 crore, according to Prabhudas Lilladher.

IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher

Net Sales are expected to increase by 14 percent Y-o-Y (up 16.8 percent Q-o-Q) to Rs. 973.5 crore, according to Prabhudas Lilladher.

Indoco Remedies Q1 PAT may dip 180.3% YoY to Rs. 9.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 26.2 percent Y-o-Y (up 9.5 percent Q-o-Q) to Rs. 268.2 crore, according to Prabhudas Lilladher.

Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.6 percent Y-o-Y (down 11 percent Q-o-Q) to Rs. 2,247.9 crore, according to Prabhudas Lilladher.

Eris Lifesciences Q1 PAT seen up 3.6% YoY to Rs. 73.8 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 5.5 percent Y-o-Y (up 12.3 percent Q-o-Q) to Rs. 237.1 crore, according to Prabhudas Lilladher.

Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 2.2 percent Y-o-Y (down 5.2 percent Q-o-Q) to Rs. 3,820.3 crore, according to Prabhudas Lilladher.

Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 15 percent Y-o-Y (up 11.6 percent Q-o-Q) to Rs. 336.1 crore, according to Prabhudas Lilladher.

Cipla Q1 PAT seen up 4.1% YoY to Rs. 465.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.7 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs. 4,257.3 crore, according to Prabhudas Lilladher.

Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 13.9 percent Y-o-Y (down 11.7 percent Q-o-Q) to Rs. 3,296.1 crore, according to Prabhudas Lilladher.

Aurobindo Pharma Q1 PAT seen up 11.2% YoY to Rs. 506.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 16.3 percent Y-o-Y (down 6.5 percent Q-o-Q) to Rs. 4,863 crore, according to Prabhudas Lilladher.

USFDA inspections go beyond factories and into corporate offices of drug cos

Indian companies will have to brace for more of such USFDA inspections as they launch specialty and complex drugs in US.

Ex-Chemistry teacher from China becomes Asia's richest self-made woman

This puts Zhong Huijuan ahead of Wu Yajun the Chairman of Longfor Group for the self-made title.